The next Em­flaza: Ac­er Ther­a­peu­tics looks to take a page out of Marathon's book

Last year, Marathon Phar­ma­ceu­ti­cals took an in­ex­pen­sive steroid avail­able for sale in the EU and Cana­da and brought it through the US FDA ap­proval process be­fore trum­pet­ing an $89,000 an­nu­al price.

The move, crit­i­cized by law­mak­ers and oth­ers, of­fered a test case for how a com­pa­ny can use FDA’s ap­proval sys­tem and the US pric­ing sys­tem to reap out­sized re­wards with­out do­ing any of the de­vel­op­ment work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER